atrial natriuretic peptide


Also found in: Thesaurus, Medical, Financial, Acronyms, Encyclopedia, Wikipedia.
Related to atrial natriuretic peptide: aldosterone, atrial natriuretic factor

atrial natriuretic peptide

n.
A peptide hormone that is produced by the right atrium of the heart in response to elevated blood pressure and stimulates the excretion of sodium and water by the kidneys. Also called atrial natriuretic factor.
References in periodicals archive ?
Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation.
A familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation.
Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamicpituitary- adrenal axis and sleep in healthy men.
Fibroblast Growth Factor is in Phase II trials for the treatment of soft tissue wounds and Auriculin(R) atrial natriuretic peptide is undergoing Phase II trials for the treatment of kidney disease.
64 ng/L, and we observed no cross-reactivity or interference with atrial natriuretic peptide (ANP), enterokinase, human airway trypsinlike protease, hepsin, LDL receptor, matriptase, spinesin, or seipins.
The data emerging from the Phase II clinical trials of our lead products, Auriculin (R) atrial natriuretic peptide, fibroblast growth factor and insulinotropin are encouraging.
Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro.
In the cardiopulmonary area, Auriculin(R) atrial natriuretic peptide is undergoing evaluation for two kidney disorders: radiocontrast induced nephropathy (RCIN) and acute renal failure.
With Auriculin(R) atrial natriuretic peptide and fibroblast growth factor (FGF) advancing toward Phase III testing, he will play a major role in guiding our products through the final stages of clinical development and the regulatory approval process.
17 /PRNewswire/ -- A Mayo Clinic researcher presented today at the American Society of Nephrology meeting preliminary results of a Phase II study supporting the potential of atrial natriuretic peptide to prevent kidney toxicity in patients undergoing diagnostic radiocontrast procedures (radiocontrast dye induced nephropathy or RCIN).
Full browser ?